203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
650 213 8444
https://soleno.life
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 33
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Anish Bhatnagar M.D. | President, CEO, COO & Director | 1,06M | N/D | 1970 |
Mr. James H. MacKaness | Chief Financial Officer | 640k | N/D | 1964 |
Ms. Patricia C. Hirano M.P.H. | Senior Vice President of Regulatory Affairs | 493k | N/D | 1966 |
Ms. Lauren Budesheim | Vice President of People | N/D | N/D | N/D |
Ms. Kristen Yen M.S. | Senior Vice President of Clinical Operations | 317,19k | N/D | 1969 |
Dr. Neil M. Cowen M.B.A., Ph.D. | Senior Vice President of Drug Development | N/D | N/D | N/D |
Ms. Meredith Manning M.B.A. | Chief Commercial Officer | N/D | N/D | 1972 |
Dr. Michael Huang M.D. | Senior Vice President of Clinical Development | N/D | N/D | 1974 |
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
L'ISS Governance QualityScore di Soleno Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.